Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5

por Entzminger, Kevin C, Fleming, Jonathan K, Entzminger, Paul D, Espinosa, Lisa Yuko, Samadi, Alex, Hiramoto, Yuko, Okumura, Shigeru C J, Maruyama, Toshiaki
Publicado 2023